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Background: Oxytocin (OXT) has been reported to act as a growth regulator in various tumor cells. However, there is a paucity of 
data on the influence of OXT on cell proliferation of corticotroph adenomas. This study aimed to examine whether OXT affects cell 
growth in pituitary tumor cell lines (AtT20 and GH3 cells) with a focus on corticotroph adenoma cells.
Methods: Reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay were conducted with AtT20 
cells to confirm the effects of OXT on hormonal activity; flow cytometry was used to assess changes in the cell cycle after OXT 
treatment. Moreover, the impact of OXT on proliferating cell nuclear antigen (PCNA), nuclear factor κB, and mitogen-activated pro-
tein kinase signaling pathway was analyzed by Western blot. 
Results: OXT treatment of 50 nM changed the gene expression of OXT receptor and pro-opiomelanocortin within a short time. In 
addition, OXT significantly reduced adrenocorticotropic hormone secretion within 1 hour. S and G2/M populations of AtT20 cells 
treated with OXT for 24 hours were significantly decreased compared to the control. Furthermore, OXT treatment decreased the 
protein levels of PCNA and phosphorylated extracellular-signal-regulated kinase (P-ERK) in AtT20 cells. 
Conclusion: Although the cytotoxic effect of OXT in AtT20 cells was not definite, OXT may blunt cell proliferation of corticotroph 
adenomas by altering the cell cycle or reducing PCNA and P-ERK levels. Further research is required to investigate the role of OXT 
as a potential therapeutic target in corticotroph adenomas.
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INTRODUCTION
Cushing’s disease (CD), the most common cause of endogenous 
Cushing’s syndrome, is caused by an adrenocorticotropic hor-
mone (ACTH)-secreting pituitary tumor (corticotroph adeno-
ma) that overproduces glucocorticoid from the adrenal cortex 
[1]. CD is associated with significant mortality and morbidity 
[1]; therefore, appropriate treatment is essential. Surgery is gen-
erally considered the initial treatment of choice for patients with 
CD. However, relatively high recurrence rates ranging from 
20% to 25% on long-term follow-up remain a challenge [2,3]. 
Radiotherapy, either alone or in combination with adrenolytic 
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drugs, may be used if surgery fails [4]. Nevertheless, none of 
the current treatment modalities ensures a full and permanent 
cure. Therefore, novel medical treatments for patients with CD 
are urgently needed. 
Oxytocin (OXT), a well-known neurohypophysial hormone, 
plays an essential role in mammalian labor and lactation [5]. In 
addition to its classical role in reproductive physiology, growing 
evidence indicates that OXT may be involved in a wide spec-
trum of neuropsychiatric functions, including prosocial behav-
ior and promotion of learning and memory. OXT can also regu-
late responses to stressors and inflammation and may be inhibit-
ed by stressful events [6]. Moreover, recent research has shown 
that OXT plays an important role in energy and bone metabo-
lism. Although the reference value of plasma OXT level in hu-
mans is not clearly established, one study demonstrated that se-
rum OXT level was lower in a group with type 2 diabetes and 
obesity than in a group with normal glucose tolerance [7]. In 
addition, high OXT level was associated with high bone mineral 
density in a 6-year prospective study of a population-based co-
hort [8]. Promoted by this background, OXT has attained re-
search attention as a potential treatment target for endocrine dis-
orders. OXT is synthesized in the hypothalamic paraventricular 
and supraoptic nuclei and released into systemic circulation via 
the neurohypophysis [9]. OXT is also produced in peripheral 
tissues, including uterus, placenta, amnion, corpus luteum, tes-
tis, gut, and heart [10,11]. Plasma OXT in humans has been re-
ported to show no diurnal variations [12], and females usually 
tend to present with higher concentration of OXT [6,13]. 
There have been several studies of the effects of OXT on pro-
liferation of various tumor cells [14,15]. OXT functions as a 
growth regulator by activating the OXT receptor in tumor cells 
[15]. In neoplastic cells derived from trophoblast or choriocarci-
noma cells [16] and small-cell lung carcinoma [17], OXT pro-
motes cell growth. On the other hand, OXT can inhibit cell 
growth in carcinomas of the endometrium [18] or ovary [19]. In 
osteosarcoma [20], breast cancer [21,22], neuroblastoma 
[23,24], and prostate cancer [25], OXT has been reported to 
show both stimulatory and inhibitory functions [14,15]. Accord-
ing to a previous research, OXT is capable of stimulating pro-
lactin release in vitro [26]. Moreover, a recent study demon-
strated that OXT can induce transient elevation of intracellular 
Ca2+ concentration in gonadotrophs, lactotrophs, and somato-
trophs, thereby mimicking secretagogues of each cell, suggest-
ing that OXT signaling might serve to coordinate the release of 
anterior pituitary hormones during specific physiological condi-
tions [27]. However, there is a paucity of data on the effects of 
OXT on cell proliferation or hormone secretion in ACTH-se-
creting tumors. 
Therefore, this study aimed to examine whether OXT affects 
cell proliferation in pituitary tumor cell lines, focusing on corti-
cotroph adenoma cells. OXT is also involved in activation of 
the mitogen-activated protein kinase (MAPK) cascade, which is 
associated with cell proliferation. The effects of OXT on MAPK 
signaling pathways and the cell cycle were also investigated to 
understand the mechanism underlying OXT effects on cell 
growth in corticotroph adenomas.
METHODS
Cell culture
Mouse pituitary corticotroph cells (AtT20, Cat No. CCL-89, 
ATCC, Manassas, VA, USA) and rat somatotroph cells (GH3, 
Cat No. CCL-82.1, ATCC) were cultured with low-glucose 
Dulbecco’s modified Eagle medium (DMEM) with 10% fetal 
bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomy-
cin. These cells (25,000 cells/cm2) were incubated in a humidi-
fied incubator at 37°C with 5% CO2. 
Immunohistochemical staining and interpretation
Immunohistochemical staining was performed to evaluate 
whether OXT receptor was expressed in normal mouse pituitary 
gland. Animal experiments were conducted according to the ap-
plicable Korean laws, reviewed and approved by the Institution-
al Animal Care and Use Committee (IACUC) of the Yonsei 
University Severance Hospital, Seoul, Korea (IACUC Approval 
No: 2015-0025), and performed in accordance with the ap-
proved guidelines by the IACUC. Deparaffinization, rehydra-
tion, and antigen retrieval were performed using CC1 (predilut-
ed; pH 8.0) antigen retrieval solution (Ventana Medical Sys-
tems, Roche Group, Tucson, AZ, USA) on the BenchMark UL-
TRA automated slide stainer (Ventana) for 64 minutes at 100°C 
(default temperature on ULTRA). After heat-induced antigen 
retrieval, rabbit polyclonal OXT receptor antibody (Cat No. bs-
1314R, dilution 1:100, Bioss Antibodies, Woburn, MA, USA) 
was incubated with samples for 15 minutes. Binding of the pri-
mary antibody was detected using an OptiView DAB IHC De-
tection Kit (Ventana) according to the manufacturer’s instruc-
tions. Intensity was defined as follows: 0 for no detectable stain-
ing, 1+ for weak reactivity mainly detectable at high magnifica-
tion (×20 to 40 objective), and 2+ or 3+ for more intense (mod-
erate or strong, respectively) reactivity easily detectable at low 
magnification (×4 objective). 
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Immunofluorescence staining and interpretation
Immunofluorescence staining for OXT receptor was performed 
in AtT20 and GH3 cells. Moreover, in order to evaluate OXT 
receptor and corticotropin-releasing hormone (CRH) receptor in 
the AtT20 cell line, cells were seeded into chamber slides and 
cultured for 24 hours. After 24 hours, the culture media was re-
moved, and 4% paraformaldehyde solution was added for 15 
minutes at room temperature to fix cells. After cell fixation, 
OXT receptor (Cat No. bs-1314R, dilution 1:200, Bioss Anti-
bodies) and CRH receptor (CRF-RI, Cat No. sc-12381, dilution 
1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) anti-
bodies were co-stained using a commercial immunohistochem-
istry kit in accordance with the manufacturer’s instructions 
(Thermo Scientific, Rockford, IL, USA). Briefly, primary anti-
body was incubated for 24 hours at 4°C, and secondary antibody 
was incubated for 3 hours at room temperature. Stained slides 
were mounted with 4′,6-diamidino-2-phenylindole (DAPI)-con-
taining mounting medium and analyzed with a confocal LASER 
microscope.
MTT assay
The effects of OXT (Cat No. 50-56-6, Cayman Chemical, Ann 
Arbor, MI, USA) or OXT receptor antagonist (L-368,899, Cat 
No. 1910, TOCRIS Bioscience, Bristol, UK) on proliferation of 
AtT20 and GH3 cells were determined by MTT assay. AtT20 
and GH3 cells (2×104 cells/cm2) were plated in 96-well plates. 
After 24 hours, cells were treated with OXT (0 to 500 nM) or 
L-368,899 (0 to 500 nM) for 24 to 48 hours, and then MTT 
(Sigma-Aldrich, St. Louis, MO, USA) dissolved in phosphate-
buffered saline was added to each well at a final concentration 
of 5 mg/mL. The cells were incubated at 37°C for 2 hours. 
Formazan (formed in plates during the assay) was dissolved in 
100 µL dimethyl sulfoxide (DMSO), and a microplate reader 
(BioTek Instruments, Winooski, VT, USA) was used to read the 
optical density of each well at 570 nm. 
Cell cycle analysis
The Cycle TEST Plus DNA Reagent Kit (BD Biosciences, San 
Jose, CA, USA) was used to analyze cellular DNA contents per 
the manufacturer’s instructions. AtT20 cells were trypsinized, 
and trypsinization was then neutralized by adding DMEM. 
Next, AtT20 cells were centrifuged at 1,800 rpm for 5 minutes. 
Cells were washed twice using wash buffer provided in the kit. 
Thereafter, cells were sequentially treated with solutions A, B, 
and C in a dark room in compliance with the manufacturer’s in-
structions. Cellular DNA contents were analyzed by flow cy-
tometry (BD FACSAria III, BD Biosciences).
Quantitative real-time polymerase chain reaction
OXT receptor and pro-opiomelanocortin (POMC) primers were 
used to confirm the effects of OXT treatment on hormonal activ-
ity in AtT20 cells. The following primers were used mouse OXT 
receptor: sense 5′-TGGCCTTCATCGTGTGCTGGA-3′, anti-
sense 5′-AGAGGAAGCGCTGCACGAGTT-3′; mouse POMC: 
sense 5′-CAGGTCCTGGAGTCCGAC-3′, antisense 5′-CAT-
GAAGCCACCGTAACG-3′; mouse glyceraldehyde-3-phos-
phate dehydrogenase: sense 5′-CTGGAGAAACCTGCCAAG-
TA-3′, antisense 5′- AGTGGGAGTTGCTGTTGAAG-3′. Total 
RNA was extracted from AtT20 cell lines with the TRIzol Re-
agent (Invitrogen, Carlsbad, CA, USA). Complementary DNA 
(cDNA) was made from 1 μg total RNA using a cDNA synthe-
sis kit (Toyobo, Osaka, Japan) according to the manufacturer’s 
instructions. Mixtures were incubated for 5 minutes at 37°C, 15 
minutes at 37°C, 5 minutes at 98°C, and then held at 4°C. Ob-
tained templates were performed using quantitative real-time 
polymerase chain reaction (qRT-PCR; 10°C, 2 minutes for 1 cy-
cle; 95°C, 10 minutes; 95°C, 15 seconds; 60°C, 1 minute for 40 
cycles) with TOPrea qPCR 2X PreMIX (Enzynomics, Daejeon, 
Korea) and run on an ABI PRISM 7900HT sequence detection 
system (Applied Biosystems, Foster City, CA, USA).
Enzyme-linked immunosorbent assay 
ACTH concentrations of the medium before and after OXT 
treatment in AtT20 cells were measured by a mouse ACTH en-
zyme-linked immunosorbent assay (ELISA) kit (AE23625MO, 
Abebio, Wuhan, China) according to the manufacturer’s in-
structions.
Western blot analysis
AtT20 and GH3 cells were used to detect changes in OXT re-
ceptor according to OXT treatment time and concentration; 
equal numbers of cells were subjected to electrophoresis on 
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) gels, and separated proteins were transferred elec-
trophoretically onto nitrocellulose membrane (0.45 µm, Bio-
Rad, Hercules, CA, USA). Proliferating cell nuclear antigen 
(PCNA) antibody (Santa Cruz Biotechnology) was used to con-
firm the effects of OXT treatment on cell proliferation. Extra-
cellular-signal-regulated kinase (ERK)1/2, phosphorylated 
ERK1/2 (P-ERK1/2), p38, P-p38, Jun N-terminal kinase (JNK), 
and phosphorylated-JUK (P-JNK) antibodies (Cat No. 9102S 
for ERK; 9101S for P-ERK; 8690S for p38; 4511S for P-p38; 
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9252S for JNK; 4671S for p-JNK, dilution 1:1,000; Cell Signal-
ing Technology, Danvers, MA, USA) were used to evaluate 
changes in the MAPK signaling pathway after OXT treatment. 
IκBa and P-IκBa (Santa Cruz Biotechnology; sc-1643 and sc-
8404, respectively) antibodies were used to investigate whether 
OXT treatment affects the nuclear factor κB (NF-κB) signaling 
pathway in AtT20 and GH3 cells. Analysis was performed after 
selective OXT receptor antagonist treatment. After blocking 
with 5% non-fat milk, the membrane was incubated with pri-
mary antibodies at room temperature for 1 hour. The membrane 
was developed with SuperSignal West Femto maximum sensi-
tivity substrate (Pierce, Rockford, IL, USA) following the man-
ufacturer’s instructions and detected with a CCD camera Las-
3000 (Fujifilm Life Science, Cambridge, MA, USA). The rela-
tive density of immunostained bands was quantified using 
Quantity One software version 4.6.1. (Bio-Rad). 
Statistical analysis
Data are presented as the mean±standard deviation (SD) or 
mean±standard error of the mean (SEM). To compare mean 
values between different groups, Student’s t test and one-way 
analysis of variance were used, followed by the Dunnett post 
hoc test. Statistical analysis was performed using IBM SPSS 
version 23.0 for Windows (IBM Co., Armonk, NY, USA). Dif-
ferences were considered statistically significant at P<0.05. 
RESULTS
OXT receptors are diffusely expressed in normal mouse 
pituitary gland and GH3 cells, and co-existence of OXT 
receptor with CRH receptor is observed in AtT20 cells 
Immunohistochemical staining was performed using paraffin 
blocks of normal mouse pituitary. Fig. 1A, 1B, and Supplemen-
tal Fig. S1 show the results of OXT receptor staining in normal 
mouse pituitary gland. As shown in Fig. 1A and 1B, normal 
mouse pituitary gland was diffusely stained for OXT receptor 
(intensity 2+; extent 80%), although OXT receptors were less 
frequently expressed in the intermediate lobe than in the anterior 
lobe (Supplemental Fig. S1). Fig. 1C illustrates the result of 
OXT receptor staining in uterine endometrial tissue, which was 
used as a positive control (intensity 3+; extent >90%). Pituitary 
ACTH is released in response to CRH and then rapidly stimu-
lates glucocorticoid synthesis in the adrenal gland. In addition, 
because CRH was reported to stimulate secretion of both OXT 
and vasopressin as well as ACTH in patients with Cushing’s syn-
drome, immunofluorescence co-staining for OXT receptor and 
CRH receptor was performed in AtT20 cells. OXT receptor and 
CRH receptor were partly co-expressed in AtT20 cells (Fig. 1D), 
although the intensity of staining for OXT receptor was weaker 
than that of CRH receptor. Moreover, as shown in Fig. 1E, F, OXT 
receptor was expressed in both AtT20 and GH3 cells.
High concentration of OXT tends to reduce cell viability in 
AtT20 cells but not GH3 cells
To evaluate the effect of OXT on cell proliferation in AtT20 
cells, cells were exposed to OXT (0 to 500 nM) for 24 hours 
(Supplemental Fig. S2A). OXT at greater than 50 nM had a ten-
Fig. 1. Expression of oxytocin (OXT) receptor in normal mouse pi-
tuitary gland and immunofluorescence staining of OXT receptor in 
AtT20 and GH3 cells. (A, B) Immunohistochemical staining shows 
that normal mouse pituitary gland was stained positively for OXT 
receptor (n=2, ×40 and ×200, respectively). (C) It indicates posi-
tive control for OXT receptor staining in uterine endometrial tissue 
(n=3, ×200). (D) It indicates immunofluorescence co-staining of 
OXT receptor (red color) and corticotropin-releasing hormone re-
ceptor (green color) in AtT20 cells (magnification, ×630). (E, F) 
These panels show the staining for OXT receptor (green color) in 
AtT20 and GH3 cells (×400), respectively. AL, anterior lobe.
A
C
E
B
D
F
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dency to slow AtT20 cell growth; cells treated with 50 nM OXT 
for 24 hours showed only a 9% increase compared to the control 
group (23.8%). Moreover, Supplemental Fig. S2B shows that 
L-368,899 (0 to 500 nM), an OXT receptor antagonist, tended 
to mitigate the effect of OXT on AtT20 cell proliferation. As 
shown in Supplemental Fig. S2C, when GH3 cells were also 
treated with OXT for 48 hours, the effects on cell growth were 
not remarkable except for a significant increase found with 500 
nM OXT. As the concentration of L-368,899 increased, GH3 
cell viability tended to decrease (Supplemental Fig. S2D).
Oxytocin can affect the cell cycle of AtT20 cells
The G0 population of AtT20 cells treated with OXT for 6 hours 
increased by about 10%, and the S and G2/M populations de-
creased by 6% or 5.5%, respectively. As shown in Fig. 2, the 
OXT-induced G0 population was slightly reduced at 6 hours by 
OXT receptor antagonist L-368,899. Moreover, in AtT20 cells 
treated with OXT and L-368,899 for 24 hours, G0 phase de-
creased by 3%, but G2/M phase increased by 2.5% compared to 
the control. After treatment with OXT for 6 or 24 hours, the S 
and G2/M populations were significantly reduced compared to 
the control; the OXT receptor antagonist recovered these popu-
lations. These results suggest that OXT may blunt proliferation 
of AtT20 cells by delaying cell division.
OXT significantly reduces gene expression of OXT 
receptor and POMC in AtT20 cells
Because pituitary ACTH is derived from the POMC precursor 
Fig. 2. Cell cycle analysis in AtT20 cells. AtT20 cells were treated with oxytocin (OXT) and/or OXT receptor antagonist L-368,899 for 6 or 
24 hours, and cells were stained with propidium iodide. DNA contents were analyzed by flow cytometer to assess cell cycle phases (n=3). 
(A) Flow cytometry of AtT20 cells treated with OXT and/or OXT receptor antagonist for 6 or 24 hours. (B, C) Representative histogram 
data of the cell cycle analysis of AtT20 cells treated with OXT and/or OXT receptor antagonist for 6 or 24 hours. PI-A, Propidium iodide-
Area. aP<0.05 vs. control group; bP<0.05 vs. L-368,899 treatment group. 
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peptide, we investigated whether OXT influences POMC gene 
expression in AtT20 cells. After treatment with 50 nM OXT, the 
mRNA levels of POMC and OXT receptor genes were estimat-
ed at each time point using qRT-PCR. As shown in Fig. 3, gene 
expression of the OXT receptor and POMC was significantly 
affected within 30 minutes by incubation with 50 nM OXT. 
Various effects on OXT receptor gene expression were induced 
according to time point. 
OXT significantly reduces ACTH level within a short time 
in AtT20 cells
To examine whether OXT affects ACTH secretion in AtT20 
cells, AtT20 cells were treated with OXT (50 nM) for 24 hours. 
The level of ACTH in medium was measured at each time point 
(baseline, 5, 15, 30 minutes, 1, 3, 6, 12, and 24 hours) using 
ELISA. Fig. 4 demonstrates that OXT significantly reduced 
ACTH level for 1 hour in AtT20 cells compared with the con-
trol; ACTH level was significantly increased at 24 hours. These 
findings suggest that OXT has different effects on ACTH secre-
tion in AtT20 cells according to time point. 
OXT treatment significantly decreases P-ERK and PCNA 
in AtT20 cells within a short time
The MAPK family is closely related to cell proliferation and 
apoptosis. To address whether the MAPK pathway may be in-
volved in the effect of OXT on AtT20 cell proliferation, PCNA, 
ERK, p38, and JNK were assayed. Because OXT has known 
anti-inflammatory effects, the effect of OXT on NF-κB signal-
ing was also investigated. As shown in Fig. 5A, after treatment 
with OXT (50 nM) for 24 hours, the protein levels of PCNA and 
Fig. 3. Effects of oxytocin (OXT) on gene expression of (A) OXT receptors and (B) pro-opiomelanocortin (POMC) in AtT20 cells. AtT20 
cells were exposed to OXT (50 nM) for 30 minutes, 1, 3, 6, 12, and 24 hours. mRNA levels of POMC and OXT receptor genes were esti-
mated at each time point using quantitative real-time polymerase chain reaction. Data are presented as mean±standard deviation (n=4 to 6). 
aP<0.05 vs. control group. 
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P-ERK were significantly reduced compared to the control 
group. However, changes in P-p38, P-JNK, and P-IκBa were 
not detected after OXT treatment in AtT20 cells (data not 
shown). Moreover, as shown in Fig. 5B, OXT receptor antago-
nist L-368,899 significantly mitigated the reduction of PCNA 
and P-ERK at 15 minutes and 24 hours compared to the control 
group. These results indicate that OXT may blunt proliferation 
of AtT20 cells by reducing PCNA and P-ERK levels. 
OXT treatment also decreases P-ERK level in GH3 cells 
within a short time
To determine whether the MAPK signaling pathway was also 
affected by OXT in GH3 cells, ERK, p38, and JNK were as-
sayed. Moreover, the effect of OXT on NF-κB signaling in GH3 
cells was investigated. After treatment with OXT (50 nM) for 
24 hours, the protein level of P-ERK was significantly reduced 
within 5 minutes compared to the control group; this change 
was maintained for 12 hours. In contrast, PCNA level was sig-
nificantly increased by OXT treatment (Fig. 6A). Additionally, 
changes in P-p38, P-JNK, and P-IκBa were not detected in GH3 
cells after OXT treatment (data not shown). Fig. 6B also dem-
onstrates that OXT receptor antagonist L-368,899 significantly 
recovered reduction of P-ERK level within 5 minutes compared 
to the control group; this change was maintained for 3 hours. 
However, after treatment with OXT receptor antagonist for 24 
hours, the protein level of PCNA was significantly reduced 
compared to that of the control group. These results suggest that 
OXT does not have an inhibitory effect on the growth of GH3 
cells, although it might affect P-ERK level in these cells.
DISCUSSION
Corticotroph adenomas account for 5% to 10% of newly diag-
nosed pituitary tumors [28]. Although the incidence of this tu-
mor is somewhat low, subjects with uncontrolled hypercorti-
solism show a 4- to 5-fold increase in overall mortality com-
pared to the general population [1]. Hypercortisolism is associ-
ated with increased risk for a variety of comorbidities, including 
arterial hypertension, diabetes mellitus, and osteoporosis [1,2]. 
Therefore, early detection and appropriate treatment are essen-
tial. The primary treatment is surgery to remove the pituitary tu-
mor [1]. However, due to high recurrence rates, patients who 
fail to achieve cure require additional treatment options, includ-
ing radiotherapy alone or in combination with adrenalectomy 
[4]; both are of limited use because of high risk of subsequent 
hormone deficiencies [4]. Furthermore, medical therapy such as 
steroidogenesis inhibitors and pituitary-directed medication 
may be effective but does show some side effect [29]; several 
Fig. 5. Effects of oxytocin (OXT) on proliferating cell nuclear antigen (PCNA) and extracellular-signal-regulated kinase 1/2 (ERK1/2) in 
AtT20 cells. AtT20 cells were incubated with (A) 50 nM OXT and/or (B) 10 nM OXT receptor antagonist L-368,899 for 24 hours, and pro-
tein levels of PCNA and ERK1/2 in cells were examined by Western blot analysis. Data are presented as mean±standard error of the mean 
(n=3). P-ERK, phosphorylated extracellular-signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. aP<0.05 vs. 
control group. 
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agents are experimental and not currently available in human 
clinical trials [4]. Hence, novel therapeutic targets for medical 
intervention are necessary in patients with CD. 
Development of pituitary tumors is a multistep process that 
involves the accumulation of a wide range of genetic and phe-
notypic alterations leading to aberrant expression of genes that 
regulate cell proliferation [30]. Evidence has shown that abnor-
mal cell signaling pathways, such as MAPK cascades, Raf, and 
Akt/protein kinase B, and alteration in tumor suppressor genes 
(e.g., P53 and RB) or oncogenes (e.g., Ras-family and pituitary 
tumor transforming gene) might be involved in the pathogenesis 
of the corticotroph adenomas causing CD [30]. Moreover, cell 
Fig. 6. Effects of oxytocin (OXT) on proliferating cell nuclear antigen (PCNA) and extracellular-signal-regulated kinase 1/2 (ERK1/2) in 
GH3 cells. GH3 cells were incubated with (A) 50 nM OXT and/or (B) 10 nM OXT receptor antagonist L-368,899 for 24 hours, and protein 
levels of PCNA and ERK1/2 in cells were examined by Western blot analysis. Data are presented as mean±standard error of the mean 
(n=3). P-ERK, phosphorylated extracellular-signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. aP<0.05 vs. 
control group. 
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cycle dysregulation is thought to be associated with develop-
ment of pituitary tumor [28,30]. Particularly, cyclin E up-regu-
lation and p27Kip1 loss-of-function may act cooperatively on de-
velopment of corticotroph adenomas [31]. Nevertheless, patho-
genetic mechanisms that underlie pituitary tumorigenesis have 
not been fully elucidated. 
OXT exerts various biological functions [14,15] and plays 
important roles in the physiology of reproduction, behavior, en-
ergy metabolism, and bone metabolism [7,8,32]. Moreover, 
OXT has anti-oxidant, anti-inflammatory, and cardioprotective 
effects; OXT treatment has reduced cardiac hypertrophy, apop-
tosis, and fibrosis [32]. Other than conventional target organs 
for OXT such as uterus and mammary gland, OXT receptor is 
expressed in many other tissues including brain, kidney, heart, 
vasculature, and bone. A variety of peripheral and central ac-
tions are all mediated by only one type of OXT receptor [13], 
which belongs to the class I family of G-protein coupled recep-
tors with a typical seven transmembrane domain structure [5]. 
For this reason, OXT and OXT receptor-associated mechanisms 
have been considered potential therapeutic targets in various 
diseases. 
The first step of this study was to identify the presence of 
OXT receptor in pituitary tissue. There is a paucity of data on 
OXT receptor expression in pituitary tumor cells, especially 
corticotroph adenoma cells. Breton et al. [33] showed the OXT 
receptor gene expression in five different pituitary cell lines, in-
cluding AtT20 and GH3 cell lines, by a semi-qRT-PCR; a posi-
tive amplification signal was detected only in lactotroph-derived 
cell lines. However, they did not directly confirm the expression 
of OXT receptor in each pituitary cell using immunohistochem-
ical or immunofluorescence stainings. In this study, OXT recep-
tors were confirmed to be present in normal mouse pituitary 
gland, AtT20, and GH3 cells. Furthermore, OXT receptor and 
CRH receptor were co-localized in AtT20 cells, indicating that 
OXT influences CRH-mediated ACTH secretion in corticotroph 
adenomas. The aggressiveness and clinical features of cortico-
troph adenomas may be determined by hormonal activity, un-
like in cancers. Shibasaki and Masui [34] demonstrated using a 
cultured pituitary adenoma of which various neuropeptides such 
as arginine vasopressin and OXT stimulate the secretion of 
POMC-derived peptides to cause Nelson’s syndrome, which is 
a rare syndrome arising from an ACTH-secreting pituitary tu-
mor after bilateral adrenalectomy. Additionally, OXT at physio-
logic concentrations was previously reported to evoke ACTH 
release from rat corticotrophs by increasing intracellular free 
calcium level mobilized from intracellular stores [35]. There-
fore, OXT may affect POMC gene expression and ACTH secre-
tion in AtT20 cells.
In our study, OXT treatment reduced the gene expression of 
OXT receptor and POMC within 30 minutes in AtT20 cells, as 
expected. In addition, ACTH level in AtT20 cells was signifi-
cantly decreased within a short time by OXT treatment com-
pared with the control, and it increased at 24 hours. Previous 
studies have shown that OXT acutely increased corticosterone 
level in rats [36]. Conversely, chronic treatment of female rats 
with OXT induces a transient increase of corticosterone, fol-
lowed by sustained suppression of the HPA axis [37]. Further-
more, OXT stimulates release of ACTH from the rat pituitary 
through arginine vasopressin receptors of the V1btype [38]. In 
human male volunteers, OXT infusion completely inhibited 
CRH-medicated ACTH secretion [39]. These findings suggest 
that the influence of OXT on the pituitary might differ accord-
ing to treatment time, drug concentration, presence of tumor, 
and species. 
Growing evidence suggests a regulatory role of OXT in the 
growth and differentiation of various cells [14,15]. Neverthe-
less, there are few studies on the effects of OXT on cell prolifer-
ation in pituitary tumor cell lines. OXT treatment can promote 
neural differentiation of adipose tissue-derived stem cells in a 
dose-dependent manner [40]. In the neoplastic context, OXT 
may act as a stimulator or inhibitor of cell proliferation in differ-
ent types of tumor cells [15]. In in vitro experiments, endome-
trial carcinoma [18] and ovarian carcinoma cells [19] were in-
hibited by OXT treatment. In contrast, OXT stimulated cell 
growth of small cell lung cancer [17] and choriocarcinoma cells 
[16]. OXT reduced cell viability in AtT20 cells but not in GH3 
cells; OXT receptor antagonist tended to recover the effect of 
OXT on AtT20 cell proliferation. To identify the underlying 
mechanism, the next question was whether OXT affects the 
MAPK signaling pathway, inflammatory process, or cell cycle, 
especially in AtT20 cells. 
In this study, OXT treatment for 24 hours in AtT20 cells sig-
nificantly reduced the protein levels of PCNA and P-ERK; GH3 
cells showed a similar pattern of change in P-ERK level to 
AtT20 cells but did not show a change in PCNA level. These 
results suggest that OXT might delay the proliferation of AtT20 
cells by reducing PCNA and P-ERK levels, unlike in GH3 cells. 
Furthermore, although the cytotoxic effect of OXT in AtT20 
cells was not definite, our findings demonstrated that OXT 
might alter the S or G2/M phase of the cell cycle to slow cell 
growth of corticotroph adenoma. However, OXT treatment does 
not seem to have a significant effect on p38 or JNK level in 
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AtT20 and GH3 cells; changes in P-IκBa were not observed in 
either cell line. 
ERK1/2 is an important regulator because it is over-phos-
phorylated in all types of pituitary tumors, including ACTH-se-
creting pituitary tumors [41]. According to the proposed mecha-
nism of cell proliferation, OXT can induce both transient and 
sustained ERK1/2 phosphorylation; while the former is related 
to cell proliferation, the latter is associated with anti-prolifera-
tive effects on the cell cycle [15]. Previous studies revealed that 
the opposite effects of OXT on cell growth were associated with 
different signaling pathways, including MAPK, cyclic adenos-
ine monophosphate (cAMP)-protein kinase A, intracellular 
(Ca2+), and the inositol pathway [14]. Additionally, Guzzi et al. 
[42] proposed that localization of the OXT receptor within the 
cell membrane plays an important role in determining the ef-
fects of OXT on cell proliferation. When the majority of OXT 
receptors is localized outside lipid rafts enriched in caveolin-1, 
OXT has an inhibitory effect on cell growth; however, if OXT 
receptors are located in lipid rafts, OXT has a strong mitogenic 
effect [42]. Based on our findings, we speculate that OXT may 
have potential to inhibit cell growth as well as hormone secre-
tion in some pituitary tumors. Therefore, further research using 
animal models is needed to clarify the effects of OXT-induced 
ERK dephosphorylation on the cell cycle in corticotroph adeno-
mas as well as other pituitary tumors. 
In conclusion, OXT is thought to regulate the physiologic ac-
tivity of AtT20 cells by controlling expression of the OXT re-
ceptor gene. OXT might have different effects on ACTH secre-
tion in AtT20 cells according to time point. Moreover, OXT 
may blunt growth of AtT20 cells by inducing changes in the cell 
cycle or reducing PCNA and P-ERK levels. In the future, more 
study is required to better understand the role of OXT-OXT re-
ceptor signaling in corticotroph adenomas, which will provide 
insight into the potential of OXT as a new therapeutic target in 
patients with CD.
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